Trial Profile
A Phase I/II Study of Immunotherapy with Milatuzumab (hLL1) in Patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2021
Price :
$35
*
At a glance
- Drugs Milatuzumab (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2009 Planned number of patients changed from 66 to 78 as reported by M.D. Anderson Cancer Center.
- 04 Nov 2008 According to the MD Anderson Cancer Center site, the planned patient number is 78.